FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor.
Ibrahim O BelloMarwah A AlrabeeahNaflaa F AlFouzanNora A AlabdulaaliPentti NieminenPublished in: Clinical oral investigations (2020)
A subset of FAK-positive ameloblastoma (as well as their malignant or metastasizing counterparts) which may have relatively aggressive behavior may be candidates for drug targeting of FAK as an additional management option.